JP2016513640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513640A5 JP2016513640A5 JP2016500441A JP2016500441A JP2016513640A5 JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5 JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016500441 A JP2016500441 A JP 2016500441A JP 2016513640 A5 JP2016513640 A5 JP 2016513640A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- drug
- sirpα
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800102P | 2013-03-15 | 2013-03-15 | |
| US61/800,102 | 2013-03-15 | ||
| PCT/US2014/018743 WO2014149477A1 (en) | 2013-03-15 | 2014-02-26 | Methods for achieving therapeutically effective doses of anti-cd47 agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Division JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513640A JP2016513640A (ja) | 2016-05-16 |
| JP2016513640A5 true JP2016513640A5 (enExample) | 2017-03-30 |
| JP6426693B2 JP6426693B2 (ja) | 2018-11-21 |
Family
ID=51580621
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500441A Active JP6426693B2 (ja) | 2013-03-15 | 2014-02-26 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Active JP7562736B2 (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018201216A Active JP6704974B2 (ja) | 2013-03-15 | 2018-10-25 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2020084674A Active JP7007422B2 (ja) | 2013-03-15 | 2020-05-13 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2022001223A Active JP7246528B2 (ja) | 2013-03-15 | 2022-01-06 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| JP2023039709A Active JP7562736B2 (ja) | 2013-03-15 | 2023-03-14 | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9623079B2 (enExample) |
| EP (3) | EP2970493B1 (enExample) |
| JP (5) | JP6426693B2 (enExample) |
| CN (3) | CN112245586A (enExample) |
| AU (4) | AU2014238105B2 (enExample) |
| CA (1) | CA2903773A1 (enExample) |
| DK (1) | DK2970493T3 (enExample) |
| ES (1) | ES2728066T3 (enExample) |
| IL (1) | IL241347B (enExample) |
| PT (1) | PT2970493T (enExample) |
| WO (1) | WO2014149477A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| CA3108119C (en) * | 2008-01-15 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| CN112245586A (zh) * | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| WO2016065245A1 (en) * | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| RU2576614C1 (ru) * | 2015-01-19 | 2016-03-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России | Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки" |
| AU2016209268B2 (en) | 2015-01-21 | 2021-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Macrophages eat cancer cells using their own calreticulin as a guide |
| ES2838925T3 (es) * | 2015-02-27 | 2021-07-02 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| HUE056769T2 (hu) | 2015-09-04 | 2022-03-28 | Primatope Therapeutics Inc | Humanizált anti-CD40 antitestek és felhasználásuk |
| WO2017049251A2 (en) | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| HK1257309A1 (zh) | 2015-09-21 | 2019-10-18 | Erasmus University Medical Center | 抗-cd47抗体及使用方法 |
| CN108367073A (zh) * | 2015-12-11 | 2018-08-03 | 小利兰·斯坦福大学托管委员会 | 以双重靶向cd47和egfr来治疗癌症 |
| EP4070812A1 (en) * | 2016-01-21 | 2022-10-12 | The Board of Trustees of the Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| US11472878B2 (en) * | 2016-04-15 | 2022-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| EP3448421B1 (en) | 2016-04-29 | 2021-11-03 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| PL3532497T3 (pl) | 2016-10-26 | 2024-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| US11286301B2 (en) | 2017-02-28 | 2022-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of CD47 blockade |
| CA3055957A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| PL3642242T3 (pl) | 2017-06-21 | 2024-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Parametry dawkowania terapii celowanych cd47 w złośliwych nowotworach hematologicznych |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| WO2019079548A1 (en) | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT |
| EP4194470A1 (en) | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| TWI831759B (zh) | 2017-12-01 | 2024-02-11 | 美商思進公司 | Cd47抗體及其用於治療癌症之用途 |
| ES2927305T3 (es) * | 2018-02-12 | 2022-11-04 | Forty Seven Inc | Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20 |
| EP3768314A4 (en) | 2018-03-21 | 2022-01-05 | ALX Oncology Inc. | ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| TW202028237A (zh) | 2018-09-27 | 2020-08-01 | 美商西建公司 | SIRPα結合蛋白及其使用方法 |
| US20220119523A1 (en) * | 2019-02-08 | 2022-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| AU2020283811A1 (en) * | 2019-05-24 | 2021-12-16 | Forty Seven, Inc. | Regimes for co-administration of immunotherapeutic agents against c-kit and CD47 |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| US20200400662A1 (en) * | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| KR102902719B1 (ko) * | 2019-10-18 | 2025-12-24 | 포티 세븐, 엘엘씨 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| CN114845710A (zh) | 2019-11-27 | 2022-08-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| US11702474B2 (en) | 2019-12-17 | 2023-07-18 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| US20250320290A1 (en) * | 2020-10-09 | 2025-10-16 | Sana Biotechnology, Inc. | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| BR112023022774A2 (pt) | 2021-05-13 | 2024-01-02 | Alx Oncology Inc | Terapias de combinação para tratamento de câncer |
| JP2024528081A (ja) * | 2021-07-28 | 2024-07-26 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 癌の治療における放射免疫療法及びｃｄ４７遮断薬の組み合わせ |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| EP4340893A1 (en) | 2021-11-19 | 2024-03-27 | KIST (Korea Institute of Science and Technology) | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell |
| JP2025502095A (ja) * | 2022-01-10 | 2025-01-24 | キニクサ・ファーマシューティカルズ，ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 移植拒絶反応のリスクを処置または低減する方法 |
| US20250302953A1 (en) | 2022-02-14 | 2025-10-02 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| JP2025540215A (ja) | 2022-12-09 | 2025-12-11 | ファイザー・インク | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| AU2002315052A1 (en) * | 2001-05-15 | 2002-11-25 | Emory University | Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2573112A1 (en) * | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| CN101456911A (zh) | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| CA3108119C (en) | 2008-01-15 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US8758750B2 (en) | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| WO2011041453A1 (en) * | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| EP4349868A3 (en) | 2010-05-14 | 2024-08-28 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EA034778B1 (ru) * | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Антитела к cd47 и способы их применения |
| US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| JP2016507555A (ja) * | 2013-02-06 | 2016-03-10 | インヒブルクス エルピー | 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法 |
| CN112245586A (zh) | 2013-03-15 | 2021-01-22 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
-
2014
- 2014-02-26 CN CN202010960541.4A patent/CN112245586A/zh active Pending
- 2014-02-26 WO PCT/US2014/018743 patent/WO2014149477A1/en not_active Ceased
- 2014-02-26 ES ES14768797T patent/ES2728066T3/es active Active
- 2014-02-26 EP EP14768797.4A patent/EP2970493B1/en active Active
- 2014-02-26 AU AU2014238105A patent/AU2014238105B2/en active Active
- 2014-02-26 PT PT14768797T patent/PT2970493T/pt unknown
- 2014-02-26 DK DK14768797.4T patent/DK2970493T3/da active
- 2014-02-26 CN CN201480015159.9A patent/CN105189556A/zh active Pending
- 2014-02-26 EP EP19166334.3A patent/EP3536709A1/en active Pending
- 2014-02-26 JP JP2016500441A patent/JP6426693B2/ja active Active
- 2014-02-26 EP EP20201319.9A patent/EP3792285A1/en not_active Ceased
- 2014-02-26 CA CA2903773A patent/CA2903773A1/en active Pending
- 2014-02-26 CN CN202210327266.1A patent/CN114917336A/zh active Pending
- 2014-02-26 US US14/769,069 patent/US9623079B2/en active Active
-
2015
- 2015-09-09 IL IL241347A patent/IL241347B/en active IP Right Grant
-
2017
- 2017-02-02 US US15/423,325 patent/US10301387B2/en active Active
-
2018
- 2018-10-25 JP JP2018201216A patent/JP6704974B2/ja active Active
-
2019
- 2019-01-17 AU AU2019200294A patent/AU2019200294B2/en active Active
- 2019-04-04 US US16/375,238 patent/US11104731B2/en active Active
-
2020
- 2020-05-13 JP JP2020084674A patent/JP7007422B2/ja active Active
- 2020-11-17 AU AU2020270485A patent/AU2020270485B2/en active Active
- 2020-11-23 US US17/102,183 patent/US11136391B2/en active Active
-
2021
- 2021-08-12 US US17/401,046 patent/US12258399B2/en active Active
-
2022
- 2022-01-06 JP JP2022001223A patent/JP7246528B2/ja active Active
- 2022-05-02 US US17/734,904 patent/US11603404B2/en active Active
- 2022-05-02 US US17/734,949 patent/US11518806B2/en active Active
-
2023
- 2023-02-03 US US18/164,252 patent/US12258403B2/en active Active
- 2023-03-14 JP JP2023039709A patent/JP7562736B2/ja active Active
-
2024
- 2024-08-20 AU AU2024210996A patent/AU2024210996A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| JP2018512391A5 (enExample) | ||
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| EA201391017A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| JP2019532047A5 (enExample) | ||
| JP2019515899A5 (enExample) | ||
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| JP2018508516A5 (enExample) | ||
| PH12013500108A1 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| EP4434540A3 (en) | Humanized anti-il-1r3 antibodies | |
| JP2016519107A5 (enExample) | ||
| RU2016151179A (ru) | Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2015511226A5 (enExample) | ||
| EA201791898A1 (ru) | Новые антитела, связывающиеся с tfpi, и содержащая их композиция | |
| JP2019530706A5 (enExample) | ||
| JP2016534996A5 (enExample) | ||
| JP2017533220A5 (enExample) |